MINNEAPOLIS--(BUSINESS WIRE)--
The worlds leading experts in the field of personalized medicine are meeting in Boston, MA September 12th and 13th 2012 for the 4th Annual Personalized Medicine Conference. This conference will tackle the issues driving, as well as restraining, the clinical delivery of personalized medicine, including coding and reimbursement, whole genome sequencing in practice, the economics of personalized medicine, Medicare policy, and market access challenges for companion diagnostics.
Personalized medicine has the potential to revolutionize medical care by utilizing an improved understanding of genetics and molecular biology to allow for better, more precise diagnostic tests, greater predictability of disease course, and improved patient safety.
Speakers and panelists will be answering the following key questions:
Is personalized medicine changing clinical practice? Can personalized medicine improve clinical outcomes? Will insurers fund the genomic revolution? What types of validation requirements are payors looking for?
At this conference, Robert C. Green, MD, MPH, Director, G2P Research Program, Associate Director for Research, Partners Center for Personalized Genetic Medicine, Brigham and Women's Hospital and Harvard Medical School will discuss the impact that whole genome sequencing will have on the practice of medicine, patients, and health care costs, as well as the potential risks associated with its use.
An important question being asked today by the medical community is What genome information is ready for clinical use? Michael Christman, Ph.D., President & CEO, Coriell Institute for Medical Research will be answering this question in a presentation which will outline how the Coriell Personalized Medicine Collaborative (CPMC) is studying the use of genomic information in clinical decision-making.
Bryan Loy, MD, Market Medical Officer, Humana will describe the various perspectives that must be considered when addressing the payment methods for molecular diagnostics. He will discuss the issue of more widely integrating personalized medicine, while keeping the health plan, the consumer, and the provider in mind.
Dora Dias-Santagata, Ph.D., Instructor of Pathology, Harvard Medical School and Co-Director, Translational Research Laboratory at Mass General, will be describing her experience in developing and implementing a clinical platform for broad-base tumor genotyping. She will also outline the challenges that arose in her clinical testing. Her presentation will also include patient cases with clinical follow-up.
Numerous other speakers will be participating. Please visit http://www.personalized-medicine-conference.com for the full list of speakers, a preliminary agenda, and information on how to register to attend.